Genor Biopharma Holdings Limited (67N0) Financial Statements
Genor Biopharma Holdings Limited Financial Overview
Genor Biopharma Holdings Limited's market cap is currently $370.47M. The company's EPS TTM is $0.31; its P/E ratio is 4.48; Genor Biopharma Holdings Limited is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 2.70B | $ 2.76B | $ 0.00 | $ 18.53M | $ 0.00 |
| Gross Profit | $ 1.76B | $ 1.78B | $ -84.96M | $ -45.04M | $ -73.21M |
| Operating Income | $ 689.46M | $ 713.61M | $ -771.77M | $ -914.26M | $ -1.11B |
| EBITDA | $ 933.65M | $ 907.79M | $ -694.88M | $ -860.58M | $ -1.05B |
| Net Income | $ 433.01M | $ 420.56M | $ -745.17M | $ -849.15M | $ -1.04B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.06B | $ 1.06B | $ 1.17B | $ 1.59B | $ 2.20B |
| Total Assets | $ 6.61B | $ 1.29B | $ 1.45B | $ 2.12B | $ 2.86B |
| Total Debt | $ 1.49B | $ 911.00K | $ 7.16M | $ 28.59M | $ 57.41M |
| Net Debt | $ 431.36M | $ -1.06B | $ -1.16B | $ -1.56B | $ -2.14B |
| Total Liabilities | $ 2.75B | $ 138.05M | $ 256.18M | $ 309.87M | $ 369.73M |
| Stockholders' Equity | $ 3.86B | $ 1.15B | $ 1.19B | $ 1.80B | $ 2.49B |
| Cash Flow | |||||
| Free Cash Flow | $ 404.05M | $ -123.55M | $ -426.15M | $ -590.56M | $ -695.13M |
| Operating Cash Flow | $ 451.73M | $ -121.98M | $ -425.12M | $ -577.61M | $ -623.74M |
| Investing Cash Flow | $ 1.24B | $ 8.01M | $ 5.99M | $ -12.94M | $ -54.26M |
| Financing Cash Flow | $ -744.78M | $ -1.56M | $ -6.82M | $ -57.39M | $ 17.57M |
Currency in CNY